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RESULTS
Loss of NER protein ERCC1 increases the number of base substitu-
tions in liver, but not in small intestinal mouse ASCs
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Figure 2. Somatic mutation rates in the genomes of ASCs from liver and small intestine of WT and 
Ercc1ǰȌ́ mice.Ǹǹ. .0./$/0/$*).ǚǸǹ*0' . .0./$/0/$*).ǚǸǹ$) '.ǚ)Ǹǹ.,0$- 
+ -0/*.*('" )*( + -2  &$).*!'$1 -Ǹ)ˆƨǹǚErcc1ǰȌ́'$1 -Ǹ)ˆƨǹǚ.(''$)/ ./$) 
Ǹ)ˆƧǹǚ)Ercc1ǰȌ́.(''$)/ ./$) Ǹ)ˆƨǹǙ--*--.- +- . )/./)- 1$/$*).Ǚ./ -$.&.- +-
- . )/.$")$ƞ)/$ơ - ) .ǸqˇƥǙƥƪǚ/2*ǰ.$ tǰ/ ./ǚ*-- /$*)ǹǙ)Ǚ.ǙǛ)*)ǰ.$")$ƞ)/Ǹqˊ
ƥǙƥƪǚ/2*ǰ.$ tǰ/ ./ǚ*-- /$*)ǹǙ
*!''.. .. .- +- *($))/'4#-/ -$5 4ǛˈǛ(0//$*).)Ǜ
ˈǛ(0//$*).Ǹ$"ǙƨǹǙ	*2 1 -ǚ/# (0//$*).+ /-*!ǰ+-*ƞ$ )/)ǰ
 ƞ$ )/.$ơ - .$")$ƞ)/'4!*-*/#/$..0 .ǸqˇƥǙƥƪǚ͓2ǰ/ ./ǚ*-- /$*)ǹǙ

)  ǚ/# - - .*( )*/' $ơ - ) .ǚ.0#.)$)- . *)/-$0/$*)*!Ǜˈ
A:T mutations in Ercc1ǰȌ́.*(+- 2$/#.Ǹ$"ǙƨǹǙ
*"$)$).$"#/$)/*/# . $ơ - ) .ǚ2 " ) -/ Ʈƫǰ#)) '(0//$*)'+-*ƞ' .
*!''.Ǹ0++' ( )/'$"ǙƩǚ0++' ( )/'$"Ǚƪǹ).. .. /# *)/-$0/$*)
of each COSMIC mutational signature (#//+ǛȌȌ) -Ǚ.)" -ǙǙ0&Ȍ*.($Ȍ.$")/0- .ǹ/*
/# 1 -" Ʈƫǰ#)) '(0//$*)'+-*ƞ' Ǹ )/-*$ǹ+ -"-*0+Ǹ0++' ( )/'$"ǙƫǹǙ





Figure 3. Mutational patterns of base substitutions acquired in the genomes of ASCs from liver 
and small intestine of WT and Ercc1ǰȌ́ mice.Ǹǹ 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reconstructed centroids are highly similar to the original centroids for all four ASC 
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Figure 4. Mutational consequences of XPCKO in human intestinal organoid cultures in vitro.Ǹǹ
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METHODS
Mouse tissue material
Ercc1ǰȌ́($ 2 - " ) -/ )($)/$) .+- 1$*0.'4 .-$ Ǹ -( $% /'Ǚǚ
ƧƥƦƫǹǙ-$ Ɵ4ǚ4-*..$)"Ercc1́ȌˁǸƪƬƫ*-&"-*0)ǹ2$/#Ercc1ˁȌ˂ mice (FVB or 
ƪƬƫ&"-*0)ǹǚErcc1ǰȌ́($ 2 - " ) -/ $)0)$!*-(ƦƪƬƫȌ#4-$
&"-*0)Ǚ$'/4+ Ʀ'$// -(/ .2 - 0. .*)/-*'.Ǚ)$('.2 - #*0. $)
$)$1$0''41 )/$'/ " .0) -.+ $ƞ+/#*" )ǰ!-  *)$/$*).$)*)/-*'' 
 )1$-*)( )/ǸƧƥǱƧƧʙǚƦƧ#'$"#/ǛƦƧ#-&4' ǹǙ3+ -$( )/.2 - + -!*-( $)
*-) 2$/# /# -$)$+' .*!*-/*-4)$('- )2$/# /# "0$ '$) .
++-*1 4/# 0/#/#$'*(($//  $)!0''*-) 2$/#0-*+ )' "$.'/$*)Ǚ
We used three 15-week old female Ercc1ǰȌ́ mice and three female WT littermates for 
*0- 3+ -$( )/.Ǚ$'.2 - #-1 ./ )./*- /ǰƧƥʙǙ$1 -.).(''$)/ ./$) .
2 - #-1 ./ )& +/*) $  $)1ˁˁˁ( $0(Ǹ1)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)Ʀʶ+ )$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! 2#*0-.0)/$'!0-/# -
+-* ..$)"Ǚ
Human tissue material
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Generation of clonal Ercc1ǰȌ́ and WT mouse organoid cultures
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 $)#*0. ǹǚ
ƪʶ
*)$/$*) ( $0(Ǹ+-*0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($ ǚƥǙƫƧƪ(ǰ /4'4./ $) ǚƦƥƥ)"Ȍ('ǰƦƥǚ
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Generation of a clonal and subclonal XPCKO organoid culture
Clonal XPCKO*-")*$0'/0- .2 - " ) -/ !-*(.(''$)/ ./$)'0'&*-")*$
0'/0-  -$1 +- 1$*0.'4 Ǹ'*&5$%' /'ǙƧƥƦƫǹ0.$)" /# 
ǰ.Ʈ" ) ǰ $/$)"
/ #)$,0 . .-$ $)Ǹ-*./ /'ǙƧƥƦƬǹǙ) '*)'#0()XPCKO organoid culture 
2.*/$) )0'/0- !*-ƬƧ4.$)#0().(''$)/ ./$)'*-")*$( $0(Ǹƪƥʶ
ƨ*)$/$*) ( $0(Ǹ+-*0 $)#*0. ǹǚƨƥʶ1ˁˁˁ( $0(ǚƧƥʶ

*)$/$*) ( $0(Ǹ+-*0 $)#*0. ǹǚƦ3ƧƬǚƦ3-$(*$)ǚƦǙƧƪ(ǰ /4'4./ $) ǚ
ƥǙƪͪƭƨǰƥƦǚƦƥͪƧƥƧƦƮƥǚƦƥƥ)"Ȍ(' - *($))/*""$)ǚ)ƪƥ)"Ȍ('#ǹǙ
0. ,0 )/'4ǚ.0'*)'0'/0- 2. -$1 *-$)"/*+-*/**'Ǹ" - /'ǙƧƥƦƭǹ.
Western blot
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0'/0- .2 - 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0ơ -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$/tmƨǙƥ'0*-*( / -Ǹ# -(*$.# -$ )/$ƞǹ2$/#/# 0$/tm 
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4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*-"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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WT mouse organoid cultures
For each mouse (three Ercc1ǰȌ́($ )/#-  '$// -(/ .ǹǚ2 + -!*-( 
. ,0 )$)" *) *)  '*)' *-")*$ 0'/0-  !-*( /#  '$1 - ) /#  .('' $)/ ./$) Ǚ
)$/$*)'.(''$)/ ./$)'*-")*$'*) 2.. ,0 ) *!($ Ƨ)ƨ
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)
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WGS and read alignment
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Base substitution and indel calling
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Validation of base substitutions in Ercc1ǰȌ́ and WT mouse organoid 
cultures
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Clonality of organoid cultures
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De novo mutational signature extraction
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Enrichment or depletion of base substitutions in genomic regions
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Calculation and comparison of mutation rates
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Analysis of mutational patterns and signatures in breast cancer 
whole-genome sequences
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Figure S2: Somatic mutation rates
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Mutational signature
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ENSMUSG00000026048 Ercc5 ǰƥǙƮƨƥ ƥǙƥƥƥ ƥǙƥƥƧ
ENSMUSG00000030094 Xpc ǰƥǙƫƧƭ ƥǙƥƦƨ ƥǙƥƩƥ
ENSMUSG00000030400 Ercc2 ǰƥǙƫƪƫ ƥǙƥƥƮ ƥǙƥƩƥ
ENSMUSG00000054051 Ercc6 ǰƥǙƪƬƦ ƥǙƥƧƮ ƥǙƥƪƧ
ENSMUSG00000003549 Ercc1 ǰƥǙƬƩƬ ƥǙƥƧƬ ƥǙƥƪƧ
ENSMUSG00000024382 Ercc3 ǰƥǙƨƥƨ ƥǙƧƦƬ ƥǙƨƥƩ
ENSMUSG00000022545 Ercc4 ǰƥǙƨƧƦ ƥǙƧƨƫ ƥǙƨƥƩ
ENSMUSG00000028329 Xpa ǰƥǙƦƪƦ ƥǙƪƧƮ ƥǙƪƮƪ
ENSMUSG00000021694 Ercc8 ƥǙƦƨƭ ƥǙƫƥƦ ƥǙƫƥƦ
SI = small intestine
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Mouse Tissue Chromosome Position Type
Ercc1 ǰȌ́1 Liver 1 19963547-19963548 CC>AT
Ercc1 ǰȌ́1 Liver 2 75869242-75869243 GG>AA
Ercc1 ǰȌ́1 Liver 2 97605553-97605554 GC>CT
Ercc1 ǰȌ́1 Liver 2 151610833-151610834 GG>TT
Ercc1 ǰȌ́1 Liver 10 49132495-49132496 TC>AA
Ercc1 ǰȌ́1 Liver 10 55373184-55373185 CT>TA
Ercc1 ǰȌ́1 Liver 17 3467736-3467737 GG>TT
Ercc1 ǰȌ́1 SI 17 83387913-83387914 GG>AA
Ercc1 ǰȌ́2 Liver 3 157520204-157520205 AA>TG
Ercc1 ǰȌ́2 Liver 5 59202560-59202561 GA>TT
Ercc1 ǰȌ́2 Liver 5 102337631-102337632 AG>GA
Ercc1 ǰȌ́2 Liver 6 111610726-111610727 AA>GG
Ercc1 ǰȌ́2 Liver 9 101601114-101601115 AC>GA
Ercc1 ǰȌ́2 Liver 10 40895371-40895372 TC>GT
Ercc1 ǰȌ́2 Liver 11 107811666-107811667 GC>TT
Ercc1 ǰȌ́2 Liver 14 50134277-50134278 TG>GT
Ercc1 ǰȌ́2 SI 4 18177691-18177692 AC>TT
Ercc1 ǰȌ́2 SI 13 54599043-54599044 CC>TT
Ercc1 ǰȌ́3 Liver 2 54244172-54244173 CC>AT
Ercc1 ǰȌ́3 Liver 4 39336415-39336416 CA>AC
Ercc1 ǰȌ́3 Liver 6 116403190-116403191 TC>GA
Ercc1 ǰȌ́3 Liver 11 70529426-70529427 TC>AA
Ercc1 ǰȌ́3 Liver 14 63208917-63208918 GC>AA
Ercc1 ǰȌ́3 Liver 15 14643203-14643204 TC>AA
WT2 Liver 10 107687236-107687237 AG>TT
WT3 Liver 1 13942075-13942076 AG>GT
WT3 SI 5 54402194-54402195 GT>TC
WT3 SI 14 13541219-13541220 CA>AT
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Mouse Tissue Chromosome Start End Size (bp) Type
Ercc1 ǰȌ́1 SI 14 98382845 98383374 529 deletion
Ercc1 ǰȌ́2 Liver 11 4307381 4308024 643 deletion
Ercc1 ǰȌ́2 Liver 11 96366839 96367238 399 deletion
Ercc1 ǰȌ́2 Liver 15 14954694 14961303 6609 deletion
Ercc1 ǰȌ́2 Liver 15 82986523 82989502 2979 deletion
Ercc1 ǰȌ́2 Liver 16 3744900 3745261 361 deletion
Ercc1 ǰȌ́2 Liver 19 25020360 25021085 725 deletion
Ercc1 ǰȌ́2 SI 3 108934215 108934569 354 deletion
Ercc1 ǰȌ́2 SI 4 88438548 88439859 1311 deletion
Ercc1 ǰȌ́2 SI 6 49000048 49000651 603 deletion
Ercc1 ǰȌ́3 Liver 15 98807785 98833375 25590 deletion
Ercc1 ǰȌ́3 SI 5 36712689 36713090 401 deletion
WT1 Liver 4 152179670 152523647 343977 deletion
WT1 Liver 17 52028043 52028582 539 deletion
WT2 Liver 19 14877486 14877950 464 deletion
WT2 SI 4 145065976 145066394 418 deletion
WT2 SI 5 41625866 41635804 9938 deletion
WT2 SI 5 41625866 41687721 61855 deletion
WT2 SI 17 35644289 35644686 397 deletion
WT3 SI 2 84747100 84747615 515 deletion
WT3 SI 6 139571588 139571908 320 deletion
+ˆ. +$-.
 




Sample Species Surveyed (bp) Total genome (bp) Callable genome (%)
Ercc1 ǰȌ́1 Liver Mouse 2217619966 2462745373 ƮƥǙƥʶ
Ercc1 ǰȌ́1 SI Mouse 2222375250 2462745373 ƮƥǙƧʶ
Ercc1 ǰȌ́2 Liver Mouse 2236641294 2462745373 ƮƥǙƭʶ
Ercc1 ǰȌ́2 SI Mouse 2234189519 2462745373 ƮƥǙƬʶ
Ercc1 ǰȌ́3 Liver Mouse 2192922359 2462745373 ƭƮǙƥʶ
Ercc1 ǰȌ́3 SI Mouse 2217427877 2462745373 ƮƥǙƥʶ
WT1 Liver Mouse 2225116951 2462745373 ƮƥǙƩʶ
WT1 SI Mouse NA NA NA
WT2 Liver Mouse 2195154888 2462745373 ƭƮǙƦʶ
WT2 SI Mouse 2201491602 2462745373 ƭƮǙƩʶ
WT3 Liver Mouse 2232884467 2462745373 ƮƥǙƬʶ
WT3 SI Mouse 2229838135 2462745373 ƮƥǙƪʶ
XPC WT1 Human 2216604591 2881033286 ƬƫǙƮʶ
XPC WT2 Human 2185992550 2881033286 ƬƪǙƮʶ
XPC WT3 Human 2115078966 2881033286 ƬƨǙƩʶ
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